Company / Total Debt
Kura Oncology, Inc. Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$9.7M
FY2025
5-year range
$9.2M / $9.7M
FY2021-FY2025
Trend
+1.9%
vs FY2024
Sector context
#78 of 83
Health Care
What the data says
Among 83 Health Care companies, Kura Oncology, Inc. is in the top 6% for total debt. Total Debt has increased for 4 consecutive years, from $4M in FY2020 to $10M in FY2025.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of +17.9%.
Increased from $9M to $10M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +1.9%
- 5-Year CAGR
- +17.9%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 83This company $9.7M Sector average $6.2B
▼
-99.8% below sector average
Key checks
Key Insights
- Kura Oncology, Inc.'s total debt has grown for 3 consecutive years.
- 5-year CAGR of +17.9%, indicating consistent growth.
- In FY2025, total debt increased 1.9% year-over-year.
- Ranks #78 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.7M | +1.9% |
| FY2024 | $9.5M | +2.0% |
| FY2023 | $9.3M | +1.9% |
| FY2022 | $9.2M | - |
| FY2021 | - | - |
| FY2020 | $4.3M | -41.4% |
| FY2019 | $7.3M | -3.3% |
| FY2018 | $7.5M | +34.7% |
| FY2017 | $5.6M | -24.0% |
| FY2016 | $7.3M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026